Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2010
05/14/2010WO2010054238A1 Factor viii formulations
05/14/2010WO2010054189A1 Role of soluble upar in the pathogenesis of proteinuric kidney disease
05/14/2010WO2010054187A2 Compositions and methods for regulating sas1r
05/14/2010WO2010054141A2 Polynucleotides encoding a human trim-cyp fusion polypeptide, compositions thereof, and methods of using same
05/14/2010WO2010054017A1 Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
05/14/2010WO2010053990A2 Crhr2 peptide agonists and uses thereof
05/14/2010WO2010053978A2 Modulation of toll-like receptor 5 expression by antisense oligonucleotides
05/14/2010WO2010053942A1 Methods for treating hepatitis c virus infection
05/14/2010WO2010053830A1 Mechanism of neuromedin u action and uses thereof
05/14/2010WO2010053596A1 Bispecific intracellular delivery vehicles
05/14/2010WO2010053561A2 Compositions and methods for dendritic cell modulation in post-ischemic wounds
05/14/2010WO2010053550A2 Cxcr4 receptor compounds
05/14/2010WO2010053548A2 Pthr1 receptor compounds
05/14/2010WO2010053547A2 Cxcr5 receptor compounds
05/14/2010WO2010053546A2 Crf1 receptor compounds
05/14/2010WO2010053545A2 Apj receptor compounds
05/14/2010WO2010053517A2 Combination therapy to combat helminth resistance
05/14/2010WO2010053199A1 Pharmaceutical composition for treating prostate cancer, and method for treating prostate cancer
05/14/2010WO2010052879A1 Aqueous composition containing follicle-stimulating hormone
05/14/2010WO2010052828A1 Pharmaceutical agent for nonischemic myocardial disorders
05/14/2010WO2010052581A1 Use of inhibitors of plac8 activity for the modulation of adipogenesis
05/14/2010WO2010052580A2 Hsc self-renewal
05/14/2010WO2010052563A2 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
05/14/2010WO2010052559A1 Cycloundecadepsipeptide compounds and use of said compounds as a medicament
05/14/2010WO2010052508A1 Ligands of vitamin d nuclear receptors with cell maturation promotion factors
05/14/2010WO2010052341A1 Anti-apoptotic fusion proteins
05/14/2010WO2010052229A1 Hla-g polypeptides and pharmaceutical uses thereof
05/14/2010WO2010052228A1 Hla-g proteins and pharmaceutical uses thereof
05/14/2010WO2010052144A2 Neuropeptide-2-receptor (y-2r) agonists and uses thereof
05/14/2010WO2010051852A1 Compositions containing interleukin-1 and peptides
05/14/2010WO2010051667A1 Pharmaceutical compositions comprising cyclic peptide nanotubes and the uses thereof
05/14/2010WO2010051631A1 Method and composition for enhancement of male erectile function
05/14/2010WO2010033884A3 Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
05/14/2010WO2010033292A9 Method for medical treatment utilizing l-glutathione
05/14/2010WO2010025483A8 Treatment of fructose malabsorption
05/14/2010WO2010025438A9 Methods of treatment using single doses of oritavancin
05/14/2010WO2010025016A3 Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response
05/14/2010WO2010023544A4 Compositions and methods for delivery of protein-coding rnas to correct mitochondrial dysfunction
05/14/2010WO2010022089A9 Derivatives of apf and methods of use
05/14/2010WO2010019847A3 Aptamer inhibition of thrombus formation
05/14/2010WO2010011439A3 Gip-based mixed agonists for treatment of metabolic disorders and obesity
05/14/2010WO2010011343A3 Methods for treating viral disorders
05/14/2010WO2010009892A3 Compositions for the treatment of pain and/or inflamation
05/14/2010WO2010009312A3 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use
05/14/2010WO2010007531A3 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia
05/14/2010WO2010005565A3 Method of treating glycogen storage disease
05/14/2010WO2010004003A3 Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
05/14/2010WO2009126349A3 Methods and compositions related to internalizing rgd peptides
05/14/2010WO2009074483A3 Insulinotropic peptide synthesis using solid and solution phase combination techniques
05/14/2010CA2779958A1 Role of soluble upar in the pathogenesis of proteinuric kidney disease
05/14/2010CA2743026A1 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
05/14/2010CA2742955A1 Bispecific intracellular delivery vehicles
05/14/2010CA2742802A1 Methods and compositions for treating complement-associated disorders
05/14/2010CA2742782A1 Endothelium mimicking nanomatrix
05/14/2010CA2742770A1 Use of inhibitors of plac8 activity for the modulation of adipogenesis
05/14/2010CA2742710A1 Crhr2 peptide agonists and uses thereof
05/14/2010CA2742659A1 Aqueous composition containing follicle-stimulating hormone
05/14/2010CA2742600A1 Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
05/14/2010CA2742531A1 Modulation of toll-like receptor 5 expression by antisense oligonucleotides
05/14/2010CA2742528A1 Apj receptor compounds
05/14/2010CA2742521A1 Hla-g polypeptides and pharmaceutical uses thereof
05/14/2010CA2742517A1 Hla-g proteins and pharmaceutical uses thereof
05/14/2010CA2742509A1 Cxcr4 receptor compounds
05/14/2010CA2742328A1 Factor viii formulations
05/14/2010CA2741991A1 Mechanism of neuromedin u action and uses thereof
05/14/2010CA2741921A1 Neuropeptide-2-receptor (y-2r) agonists and uses thereof
05/14/2010CA2741829A1 Cycloundecadepsipeptide compounds and use of said compounds as a medicament
05/13/2010US20100121253 Method and Apparatus of Low Strength Electric Field Network-Mediated Delivery of Drug, Gene, SI-RNA, SH-RNA Protein, Peptide, Antibody or Other Biomedical and Therapeutic Molecules and Reagents in Solid Organs
05/13/2010US20100121039 Methods and compositions for prolonging elimination half-times of bioactive compounds
05/13/2010US20100121027 Cyclic Peptide Compositions for Treatment of Sexual Dysfunction
05/13/2010US20100120892 Methods and compositions for the inhibition of stat5 in prostate cancer cells
05/13/2010US20100120700 Methods and compositions for treating cervical cancer
05/13/2010US20100120699 Method for synthesizing kpv tripeptide diamide derivates
05/13/2010US20100120698 Low-fat food
05/13/2010US20100120697 Tumor Activated Prodrugs
05/13/2010US20100120696 Peptides Having Activities of Epidermal Growth Factor and Its Uses
05/13/2010US20100120695 Polypeptides that bind membrane proteins
05/13/2010US20100120694 Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
05/13/2010US20100120693 Medicament for improving prognostic survival in therapy of malignant tumor
05/13/2010US20100120692 Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
05/13/2010US20100120691 Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
05/13/2010US20100120690 Polypeptides Having Antimicrobial Activity and Polynucleotides Encoding Same
05/13/2010US20100120689 Polymer factor viii moiety conjugates
05/13/2010US20100120688 ErbB Interface Peptidomimetics And Methods Of Use Thereof
05/13/2010US20100120687 Modulating apoptosis
05/13/2010US20100120686 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
05/13/2010US20100120685 Methods and compositions for the treatment of cancer
05/13/2010US20100120684 Mutants of interleukin- 1 receptor antagonist and uses thereof
05/13/2010US20100120683 Prame derived peptides and immunogenic compositions comprising these
05/13/2010US20100120682 Compositions for increasing body weight, use and methods
05/13/2010US20100120681 Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
05/13/2010US20100120680 Method of treating hepatitis c virus
05/13/2010US20100120679 Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy
05/13/2010US20100120678 Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface
05/13/2010US20100120677 Activity of recombinant equine follicle stimulating hormone
05/13/2010US20100120676 Composition to treat and/or prevent gastrointestinal infection
05/13/2010US20100120675 Inhibitor of the uracil-dna glycosylase enzyme and uses thereof
05/13/2010US20100120674 Insulin resistance improving agents
05/13/2010US20100120673 Bacteriophage lysins for bacillus anthracis
05/13/2010US20100120672 cyclic peptide compounds
1 ... 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 ... 3163